Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement

Conditions:   Human Papilloma Virus;   Recurrent Respiratory Papillomatosis Interventions:   Drug: Lenvatinib;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Eisai Inc.;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials